Hot Investor Mandate 2: Corporate VC Invests Strategically in Early Stage Drugs

2 Feb

The corporate investment arm of an Asia-based pharma firm is focused on early stage therapeutic companies that are a strategic fit for its parent company. Typical equity investments range from $0.5-5 million. The firm is also open to other forms of partnerships such as collaborative research, licensing, and M&A. The firm is currently seeking opportunities from across the US with a focus in the Bay Area.

The firm is looking opportunistically across all therapeutic subsectors from small molecules to biologics, gene therapy and cell therapy. The firm is most interested in assets in pre-IND to Phase II stages. The firm is agnostic to disease indications.

The firm is looking for experienced management team with strong sector knowledge. The firm may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: